Up to 40% of patients with non-small cell lung cancer (NSCLC) develop central nervous
system (CNS) metastases. Current treatments for this subgroup of patients with advanced …

The central nervous system (CNS) is less prone to infection owing to protection from the
brain-blood barrier. However, craniotomy destroys this protection and increases the risk of …

Lung cancer patients are at risk for brain metastases and often succumb to their intracranial
disease. Chimeric Antigen Receptor (CAR) T-cells emerged as a powerful cell-based …

Objectives Stereotactic radiosurgery (SRS), a therapy that uses radiation to treat brain
tumors, has become a significant treatment procedure for patients with brain metastasis …

Objectives The first treatment strategy for brain metastases (BM) plays a pivotal role in the
prognosis of patients. Among all strategies, stereotactic radiosurgery (SRS) is considered a …

For many tumor entities, tumor biology and response to therapy are reflected by components
that can be detected and captured in the blood stream. The so called “liquid biopsy” has …

Background Brain metastases (BM) represent the most frequent intracranial tumors with
increasing incidence. Many primary tumors are currently treated in protocols that incorporate …

Background Metastases are the most common malignant tumors affecting the central
nervous system and occur in 20–40 percent of patients with solid systemic tumors. The aim …

Abstract Before the Stereotactic Radiosurgery (SRS) treatment, it is of great clinical
significance to avoid secondary genetic damage and guide the personalized treatment …

Targeted radionuclide therapy is an emerging therapeutic concept for metastatic cancer that
can be considered if a tumor can be delineated by nuclear medicine imaging and also …